The U.S. Navy has awarded a contract for $1.25 million to Vical Incorporated (Nasdaq:VICL) for large-scale cGMP vaccine manufacturing and related clinical and regulatory preparations, which are already underway, for a Phase 1 clinical trial of the company’s vaccine against A/H1N1 pandemic influenza. The trial will be conducted in collaboration with the U.S. Naval Medical Research Center. Vical was the first company to produce a vaccine against the A/H1N1 influenza virus after the initial reports of widespread outbreaks in Mexico, and the first to announce immunogenicity results from animal testing in two species.

Read the release.